{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:49:04Z","timestamp":1793969344239,"version":"4.8.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.eururo.2025.12.022","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:23:59Z","timestamp":1767212639000},"page":"204-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Gu\u00e9rin (BCG) in BCG-na\u00efve High-risk Non\u2013muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6126-9889","authenticated-orcid":false,"given":"Pietro","family":"Scilipoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Zaurito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Longoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Colecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.12.022_b0005","doi-asserted-by":"crossref","unstructured":"Scilipoti P, Longoni M, de Angelis M, et al. Long-term oncological outcomes for patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin (BCG): a comparative analysis of adequate versus inadequate BCG treatment. Eur Urol Focus. Published online May 19, 2025. https:\/\/doi.org\/10.1016\/j.euf.2025.04.033.","DOI":"10.1016\/j.euf.2025.04.033"},{"key":"10.1016\/j.eururo.2025.12.022_b0010","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.euo.2025.03.007","article-title":"Oncological outcomes in bacillus Calmette-Gu\u00e9rin\u2013na\u00efve high-risk non\u2013muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives","volume":"8","author":"Longoni","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.12.022_b0015","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1038\/s41598-017-06002-8","article-title":"Molecular mechanism of PD-1\/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2025.12.022_b0020","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.12.022_b0025","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2025.12.022_b0030","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2025.12.022_b0035","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"de Santis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.12.022_b0040","doi-asserted-by":"crossref","unstructured":"Roupret M, Bertaut A, Pignot G, et al. ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC). Ann Oncol. In press. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.017.","DOI":"10.1016\/j.annonc.2025.09.017"},{"key":"10.1016\/j.eururo.2025.12.022_b0045","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.12.022_b0050","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.12.022_b0055","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0140-6736(25)02015-X","article-title":"Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer","volume":"406","author":"Necchi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.12.022_b0060","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"}],"updated-by":[{"DOI":"10.1016\/j.eururo.2026.02.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000}},{"DOI":"10.1016\/j.eururo.2026.02.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825048778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825048778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:30:50Z","timestamp":1771615850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825048778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0302283825048778"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.12.022","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Gu\u00e9rin (BCG) in BCG-na\u00efve High-risk Non\u2013muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}